Sydney, July 13, 2007 AEST (ABN Newswire) - Following significant shareholder enquiry, the Company provides an update of the status of the international clinical trial currently underway for HeartWare's (ASX: HTW) HVAD TM Left Ventricular Assist Device.
Following recent successful implants at Hannover Medical Centre, Royal Perth Hospital and St Vincent's Hospital in Sydney, the HVAD TM pump has now been implanted in 16 patients. On a cumulative basis these patients have been supported by the device for over 2,400 days. The average support duration across the group exceeds 150 days per patient.
15 out of the 16 patients are alive and well, with all but the three most recent patients having long been discharged from hospital. Of the 16 patients, 7 have now successfully passed the primary endpoint of the clinical trial, namely survival to 180 days or to the point of undergoing heart transplantation. Three of our patients have received heart transplants, after being supported by their pumps for 427, 348 and 157 days respectively.
The pump continues to demonstrate very promising clinical results. We are confident of completing our 20 patient target enrolment in the trial over coming weeks.
Contact
www.heartware.com.au
Howard Leibman
Director Corporate Development
HeartWare Limited
+61 2 9238 2064 / 0402 440644
| ||
|
